AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

PRESS RELEASE

AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH VERY UNFAVORABLE GENETIC PROFILES, ARE RESPONDING TO TREATMENT

• The combination treatment is well-tolerated, with no hematological toxicity
• The disease control rate is 100% (3/3)
• The partial response rate is 100% (3/3), including one patient in complete remission
• These results were obtained after the first cycle of treatment (14 days of treatment) in patients receiving third- or fourth-line treatment, two of whom had previously progressed on venetoclax in combination with other chemotherapies
• These three patients all have very difficult to treat cytogenetic profiles, including TP53 mutation and complex karyotypes, gene mutations that typically have a poor prognosis due to their aggressive disease course and treatment resistance
• Phase 1 continues with a new stage that will evaluate a higher dose of AB8939, still in combination with venetoclax
• These results corroborate the mechanism of action of AB8939, which is capable of destabilizing microtubules by evading multi-drug resistance and targeting cancer stem cells without eliminating non tumoral stem cells
  
  

AB SCIENCE WILL HOLD A VIRTUAL CONFERENCE ON THIS TOPIC ON THURSDAY, OCTOBER 16, 2025, FROM 2PM TO 3PM CET WITH THREE RENOWNED EXPERTS IN AML

• Prof. Nicholas J. Short, MD, Associate Professor and Co-Lead of Section of Developmental Therapeutics, Department of Leukemia, MD Anderson Cancer Center
• Prof. Olivier Hermine, MD, PhD, Head of the Hematology Department at Necker-Enfants Malades Hospital, Paris, France
• Prof. Christian Auclair, (PharmD, PhD), Emeritus Professor
  
  

Paris, October 14, 2025, 8.30am

AB Science SA (Euronext - FR0010557264 - AB) today provides an update on the Phase 1 study of the molecule AB8939 and, in particular, on the initial clinical data for the combination of AB8939 + Venetoclax in the first three patients with acute myeloid leukemia (AML) associated with a very unfavorable genetic profile.

AB8939 is a drug candidate that jointly targets cancer cells by destabilizing microtubules, which are essential for cell division, and also targeting cancer stem cells by inhibiting enzymes (ALDH1A1 and ALDH2) that are essential for maintaining their physiological state and survival.

AB8939 is currently being evaluated in a Phase 1 clinical trial (study AB18001, NCT05211570) in patients with refractory and relapsed AML.

The Phase 1 clinical trial of AB8939 has completed its first two stages, which consisted of determining the maximum tolerated dose (MTD) after 3 and 14 consecutive days of monotherapy, respectively. In both cases, the MTD was 21.3 mg/m².